Numerous phosphocalcium alterations associated with bone mineral density in hypertension have been described, but very few studies assess them. This study assesses bone mass in hypertensive postmenopausal women and the hypertension influence determining both calcium homeostasis and bone turnover markers. Blood and urine samples were analysed for calcium metabolism-related parameters. Densitometry studies were conducted in the lumbar spine (L2-L4). Hypertensive osteoporotic womenFselected from 82 women, with 22% osteoporosis prevalence, similar to the rate for the same age in the Spanish populationFhad significantly higher levels of body mass index (29 7 4 vs 26 7 4, P ¼ 0.019), calciuria (293 7 146 vs 210 7 116 mg/ 24 h, P ¼ 0.023) and calcium/creatinine ratio (0.33 7 0.2 vs 0.22 7 0.1 P ¼ 0.003) vs hypertensive nonosteoporotic women. No relation was found between systolic and diastolic blood pressure with bone mass. However, there was a negative osteocalcin correlation (r ¼ À0.386, P ¼ 0.0001, and r ¼ À0.242, P ¼ 0.033). Calciuria is associated with bone mass decrease in hypertensive women, and there is no relation between bone mass and blood pressure.
Introduction
The financial and social costs of hypertension and osteoporosis, clinically silent diseases, are determined by the disease consequences, such as vascular disease and fractures. The relation between these illnesses has not been clearly established. Many extracellular calcium metabolism alterations have been hypertension associated, which could determine the bone mass level in this patient group, including an increase in urinary calcium excretion for a given sodium intake, evidence of secondary increase in parathyroid gland activity, increase in urinary cyclic AMP, tendency to low serum ionized calcium, raised plasma calcitriol and increased intestinal calcium absorption. [1] [2] [3] [4] [5] [6] The lack of studies relating these two diseases is surprising, because 50% of the hypertensive population consists of postmenopausal women for whom osteoporosis represents an important health problem. In animal studies, hypertensive rats show that hypercalciuria and ensuing hyperparathyroidism lead to reduced growth and a decrease in total bone mineral density (BMD) later in life. 7 Cappuccio et al 8 studied the relation between bone mass and blood pressure in white postmenopausal women. They found an inverse association between these two parameters, but only with the highest blood pressure values. However, it is unclear whether hypertension might be associated with reduced BMD in humans. The hypercalciuria of hypertension can produce an increase in parathyroid gland activity because of a decrease in the serum calcium. The high level of PTH produces an increase in bone turnover. The increase of turnover causes BMD decrease. The turnover is measured by biochemical markers such as osteocalcin and deoxypyridinoline. 9 This study was designed to evaluate the effect of calcium metabolism alteration on BMD and bone remodelling markers in hypertensive women.
Materials and methods

Subjects and study protocol
According to the Joint National Committee (JNC VI) criteria, 82 women between 36 and 76 years (average age 59 7 10 years) with mild-moderate hyper-tension were included in the study. During clinic visits, a medical history was obtained by a standard questionnaire. Exclusion criteria were chronic alcohol abuse, neoplasia, secondary arterial hypertension, chronic renal insufficiency, hyper-and hypocalcemia, diabetes, hyperparathyroidism and use of a modifying bone mass drug. The average time for hypertension development was 65 7 84 months (median 51 months, IQR (interquartile range) 12-120) and 90% of the women were postmenopausal (74 subjects).
In a group of 40 nonhypertensive postmenopausal women, with a body mass index (BMI) and age coherent with the studied population, we measured BMD, sodium, calcium and creatinine in urine after 24 h, as a control.
Measurements
Blood samples were obtained after 8 and 9 fasting hours. Total calcium, phosphorous, magnesium and alkaline phosphatase were measured by a Hitachi 917 auto analyzer (Tokyo, Japan). Ionic calcium, sodium, creatinine, calcium and phosphorus levels in urine were assessed with an ion-selective electrode (Nova-7, Nova Instruments, USA). Osteocalcin was measured using a commercial RIA test (Schering, Germany) with a 6.7% interassay variation coefficient. PTHi levels were determined by chemoimmunoluminescence (Immulite DPC, Los Angeles, USA) with a 6% interassay variation coefficient. 25-Hydroxy vitamin D levels were determined by HPLC with a 12% interassay variation coefficient, and 1.25-hydroxy vitamin D levels were determined by RIA with a 12% interassay variation coefficient.
Urinary deoxypyridinoline levels were determined by chemoimmunoluminescence after 24 h (Immulite DPC, Dipesa, Los Angeles, USA). The results were expressed in relation to the excretion of creatinine with a 14% interassay variation coefficient.
Densitometry studies were conducted in the lumbar spine (L2-L4) using an Rx densitometer (DEXA, Lunar Corporation, Madison, WI, USA). BMD result was expressed in g/cm 2 and as peak bone mass percentage in normal subjects (T-score) and subjects percentage of the same age and sex (Z-score), depending on the software used. Women with a T-score oÀ2.5 were considered osteoporotic.
Statistical analyses
The results are expressed as mean 7 s.d. The differences were tested by the Mann-Whitney nonparametric U-test. The relation between normally distributed variables was assessed using Pearson's correlation coefficient and Spearman's method for nonnormally distributed variables.
In order to evaluate the differences in BMD of 8%, with an a range of 0.050 and a b range of 0.10, 82 patients were needed. The statistical significance was Pp0.05.
Ethical issues
This study was approved by the hospital ethics committee and patients signed an informed consent form to participate.
Results
In total, 82 patients (average age of 59 7 9 years, BMI of 28 7 4 kg/m 2 ) were analysed. Of these, 46% of hypertensive patients were overweight. Mean values for systolic blood pressure (SBP) and DBP were 155 7 22 and 93 7 9 mmHg, respectively. Table 1 shows the analytical parameters related to calcium metabolism, bone turnover markers and densitometry values. Mean values of determined parameters were within the normal range, except for the urinary calcium/creatinine ratio. Table 2 shows that hypertensive postmenopausal BMD is similar to nonhypertensive postmenopausal BMD, with comparable osteoporosis percentages (22 vs 25%). Only calciuria is higher within the hypertensive (Table 3) , the only statistically significant differences were BMI (29 7 4 vs 26 7 4, P ¼ 0.019), calciuria (293 7 146 vs 210 7 116 mg/24 h, P ¼ 0.014) and calcium/creatinine ratio (0.33 7 0.2 vs 0.22 7 0.1 P ¼ 0.003). No relation was observed between SBP and DBP and bone mass, but there was a statistically significant negative correlation between osteocalcin and SBP (r ¼ À0.386, P ¼ 0.0001) and DBP (r ¼ À0.242, P ¼ 0.033). BMD was related to age (r ¼ À0.336, P ¼ 0.034), BMI (r ¼ 0.353, P ¼ 0.001) and calcium/ creatinine ratio (r ¼ À0.261, P ¼ 0.023).
Discussion
In our study, the percentage of osteoporotic women was 22% (the average Spanish osteoporotic population is 10%) but applicable to similar age groups (22 vs 22.8%). 10 No differences were observed in the nonhypertensive menopausal population. When hypertensive women were divided into osteoporotic and nonosteoporotic groups, they presented differences in age, BMI (both with a similar significance), calciuria and calcium/creatinine ratio.
No relation between bone mass and blood pressure was observed in lineal correlations. Tsuda et al 11 observed an inverse relation between SBP and bone mass. Nevertheless, these authors assessed BMD by lateral densitometry and the studied population was smaller than ours. Cappuccio et al 8 observed that the rate of bone loss at the femoral neck increased with blood pressure at baseline. Only the high blood pressure population showed the effect. Our study is cross-sectional, whereas Cappuccio's was prospective. There is no data relation between the baseline BMD and blood pressure. Moreover, we measure spine BMD and Cappuccio et al 8 measured proximal femur BMD. We have observed a statistically significant inverse relation between osteocalcin and blood pressure (both systolic and diastolic). Osteocalcin is a bone turnover marker. Its increase is associated with a decrease in BMD, whereas turnover increase is most probably related to hypercalciuria, which is the most frequent calcium metabolism disorder in hypertensive subjects. There was an inverse relation between calciuria and bone mass. These data are similar to those described by other authors.
The cause of hypercalciuria in hypertensive subjects is unknown. However, central blood volume hypothesis and renal calcium leak hypothesis have been suggested. In central blood volume hypothesis, hypercalciuria is caused by central volume expansion observed in hypertensive patients; in renal calcium leak hypothesis, hypercalciuria is caused by loss of calcium because of a tubular disorder. 12 Recently, Cruz et al 13 have described the association between NCCT (Na-Cl cotransporter of the distal convoluted tubule) mutations and an increase in bone mass in patients with Gitelman's syndrome, characterized by hypokaliaemia, metabolic alkalosis, hypocalciuria, hypomagnesaemia and blood pressure decrease. Patients homozygotic for this mutation presented higher BMD than heterozygotic patients. Some authors suggest that mutations of this cotransporter could be the link between osteoporosis and hypertension.
14 Moreover, this cotransporter was found in osteoblasts, one of the sites where thiazides inhibit the cotransporter and calcium intracellular amount increase. 15 Our results show that an increase in calciuria is associated with the decrease of BMD in hypertensive women, although other factors (genetics and non genetics) may be involved. Antihypertensive drugs have a variable effect on calciuria, which represents an additional criterion in the selection and individualization of therapy.
